Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy

Acta Ophthalmologica

Volumn 86, Issue 6, 2008, Pages 694-695

  Querques, Giuseppe ^a,b   Angulo Bocco, Maria C ^a   Soubrane, Gisele ^a   Souied, Eric H ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; BIOMICROSCOPY; CASE REPORT; CLINICAL FEATURE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; LETTER; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA VITELLIFORM DEGENERATION; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INDOCYANINE GREEN; INJECTIONS; MACULAR DEGENERATION; MALE; PIGMENT EPITHELIUM OF EYE; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 51049105743     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01132.x     Document Type: Letter

References (5)

1. Brown DM, Kaiser PK, Michels M et al. (2006): Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355: 1432-1444.
2. Leu J, Schrage NF & Degenring RF (2007): Choroidal neovascularization secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol: 245: 1723-1725.
3. Miller AS, Bresnick GH & Chandra SR (1976): Choroidal neovascular membrane in Best's vitelliform macular dystrophy. Am J Ophthalmol 82: 252-255.
4. Noble KG, Scher BM & Carr RE (1978): Polymorphous presentations and vitelliform macular dystrophy: Subretinal neovascularization and central choroidal atrophy. Br J Ophthalmol 62: 561-570.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY & MARINA Study Group (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419-1431.